Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491121 | 0.85 | LRRK2 (0.37) | SMN1; SMN2GAARXRANR4A2L3MBTL1 | |
| SCHEMBL2189399 | 0.82 | THRB (0.43) | THRBSMN1; SMN2GAALMNAHTT | |
| SCHEMBL5496929 | 0.77 | CRHR1 (0.40) | SMN1; SMN2GAAMEN1KMT2AMAPT | |
| SCHEMBL5845356 | 0.76 | THRB (0.46) | THRBSMN1; SMN2LMNAHTTMEN1 | |
| SCHEMBL4769088 | 0.75 | THRB (0.38) | THRBSMN1; SMN2LMNAHTTMEN1 | |
| SCHEMBL4503972 | 0.75 | LRRK2 (0.38) | SMN1; SMN2GAAL3MBTL1MEN1KMT2A | |
| SCHEMBL3270971 | 0.75 | THRB (0.38) | THRBSMN1; SMN2LMNAHTTMEN1 | |
| SCHEMBL5106936 | 0.74 | THRB (0.36) | THRBMEN1KMT2AMAPTPIK3CG | |
| SCHEMBL3277032 | 0.71 | GAA (0.39) | SMN1; SMN2GAAL3MBTL1LMNAHTT | |
| SCHEMBL4847932 | 0.70 | RXRA (0.50) | SMN1; SMN2RXRANR4A2L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | disclosed |
| US-7462622-B2 | Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1395591-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-04 | — | — | EP | disclosed |
| EP-1383747-B1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-25 | — | — | US | disclosed |
| US-20050054661-A1 | Corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-05-06 | — | — | US | disclosed |
| EP-1395591-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1383747-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | disclosed |
| US-6531475-B1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6514982-B1 | Corticotropin releasing factor is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotropic hormone, beta -endorphin, and other pro-opiomelanocortin-derived peptides from the pituitary | NEUROCRINE BIOSCIENCES, INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002100863-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002088095-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| EP-1129091-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1129091-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027846-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR1, NR3C2, CRHR2 | THRB 472/4885SMN1; SMN2 3296/4885GAA 4720/4885 |
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | THRB 400/4885SMN1; SMN2 786/4885GAA 2746/4885 |
| US-20050054661-A1 | Corticotropin releasing factor antagonists | CRHR1, CRH, CRHR2 | THRB 447/4885SMN1; SMN2 4224/4885GAA 4516/4885 |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | THRB 508/4885SMN1; SMN2 3066/4885GAA 2832/4885 |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | THRB 400/4885SMN1; SMN2 786/4885GAA 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.